Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes
NCT ID: NCT01704378
Last Updated: 2017-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
89 participants
INTERVENTIONAL
2001-04-18
2003-03-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes
NCT01467323
Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs
NCT01486862
Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes
NCT01487798
Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes
NCT00600366
Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes
NCT01520818
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BIAsp
biphasic insulin aspart
Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biphasic insulin aspart
Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Completed the trial BIAsp-1236
Exclusion Criteria
* Known or suspected allergy to trial products or related products
* Women who are having the intention of becoming pregnant, or are judged not to be using adequate contraceptive measures
* Any other significant condition or concomitant disease or any condition that would interfere with participation as judged by the Investigator
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Kotka, , Finland
Novo Nordisk Investigational Site
Kuopio, , Finland
Novo Nordisk Investigational Site
Lahti, , Finland
Novo Nordisk Investigational Site
Gjøvik, , Norway
Novo Nordisk Investigational Site
Horten, , Norway
Novo Nordisk Investigational Site
Kirkenær, , Norway
Novo Nordisk Investigational Site
Kongsvinger, , Norway
Novo Nordisk Investigational Site
Notodden, , Norway
Novo Nordisk Investigational Site
Falun, , Sweden
Novo Nordisk Investigational Site
Helsingborg, , Sweden
Novo Nordisk Investigational Site
Motala, , Sweden
Novo Nordisk Investigational Site
Derby, , United Kingdom
Novo Nordisk Investigational Site
Edinburgh, , United Kingdom
Novo Nordisk Investigational Site
Hull, , United Kingdom
Novo Nordisk Investigational Site
Liverpool, , United Kingdom
Novo Nordisk Investigational Site
Scarborough, , United Kingdom
Novo Nordisk Investigational Site
Wirral, Merseyside, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BIASP-1386
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.